Latest Pulmonary Embolism News

Page 2 of 2
Cyclopharm Limited reports a 26% revenue jump to $15.42 million in H1 2025, driven by rapid U.S. expansion and extended patent protections for its Technegas® lung imaging technology.
Ada Torres
Ada Torres
27 Aug 2025
Cyclopharm Limited reported a 26% revenue increase for the half year ended June 2025, driven by rapid US market expansion and strong growth in its Third-Party distribution business. Despite a wider net loss, the company secured a key patent extension and reaffirmed its target to install 250-300 Technegas® systems in the US by late 2026.
Ada Torres
Ada Torres
27 Aug 2025
Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.
Ada Torres
Ada Torres
11 June 2025
4DMedical has submitted its CT:VQ™ software to the FDA, aiming to revolutionize lung ventilation and perfusion imaging by replacing traditional nuclear scans with a non-contrast CT-based solution.
Ada Torres
Ada Torres
26 May 2025
4DMedical has landed a significant commercial contract with Intermountain Health to deploy its FDA-cleared Pulmonary Hypertension Analysis (PHA™) product, marking a key milestone in its U.S. expansion through a strategic Microsoft-backed partnership.
Ada Torres
Ada Torres
5 May 2025
Cyclopharm has inked a pivotal three-year agreement with HCA Healthcare, enabling deployment of its Technegas® lung imaging technology across up to 169 US nuclear medicine departments. This deal marks a major step in expanding Technegas®’ footprint in the American healthcare market.
Ada Torres
Ada Torres
23 Jan 2025